title: [Prevalence of HCV, HBV and HIV infections among severe Polish haemophiliacs].
abstract: In the past, haemophilia replacement therapy was based on fresh frozen plasma, cryoprecipitate and blood transfusions--i.e. preparates not subjected to any viral inactivation methods. The aim of the present study was to assess the prevalence of HCV, HBV and HIV infections among Polish haemophiliacs.
  
  
  METHODS
  Severe haemophilia patients were divided into two age groups according to the type of replacement therapy used in the past: group 1--172 patients born 1935-1990, group 2--41 patients born 1991-2002. The following viral markers were tested: anti-HCV, RNA HCV (if needed--virus genotype), HBsAg and anti-HIV. In 75 patients / group 1 and 41 / group 2, anti-HBc presence was determined.
  
  
  RESULTS
  In group 1, 95% of patients were anti-HCV positive and in 77.3% RNA HCV was detected. The most prevalent was lb genotype (58.6%) followed by 3a (27%). HBsAg was found in 8.7% cases of group 1. Anti-HCV antibodies were detected in 51 of 75 (68%) patients of this group. One patient was anti-HIV positive. In only one patient of group 2 (2.4%) viral markers were detected (anti-HCV and RNA HCV).
  
  
  CONCLUSIONS
  Nowadays, the risk of HCV, HBV and HIV infection in Polish severe haemophiliacs is very low.
authors.affiliation: Klinika Zaburzeń Hemostazy i Chorób Wewnetrznych. jwindyga@ihit.waw.pl
authors.forename: Jerzy
authors.initials: J
authors.lastname: Windyga
authors.forename: Piotr
authors.initials: P
authors.lastname: Grabarczyk
authors.forename: Ewa
authors.initials: E
authors.lastname: Stefańska
authors.forename: Anna
authors.initials: A
authors.lastname: Buczma
authors.forename: Andrzej Bogusław
authors.initials: AB
authors.lastname: Szczepanik
authors.forename: Anna
authors.initials: A
authors.lastname: Klukowska
authors.forename: Maria
authors.initials: M
authors.lastname: Mikulska
authors.forename: Joanna
authors.initials: J
authors.lastname: Medyńska
authors.forename: Ewa
authors.initials: E
authors.lastname: Brojer
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000453:epidemiology* / Q000276:immunology; D006467:Hemophilia A / Q000453:epidemiology*; D002836:Hemophilia B / Q000453:epidemiology*; D006509:Hepatitis B / Q000453:epidemiology* / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000097:blood; D006526:Hepatitis C / Q000453:epidemiology* / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors
chemical_list: D015483:HIV Antibodies; D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies